PROPANE: An open label phase 2 study on propranolol and pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma – a Scandinavian Sarcoma Group collaboration

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513727-16-00

Acronym

SA2115

Enrollment

Registered

2024-05-23

Start date

2022-12-05

Completion date

Unknown

Last updated

2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma

Brief summary

Percentage of patients alive with CR, PR and SD according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) at 3 months

Detailed description

Percentage of patients with CR and PR, including duration hereof using RECIST v 1.1, Median PFS and OS, Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE) v5.0, The 30 item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) questionnaire

Interventions

DRUGPROPRANOLOL HYDROCHLORIDE

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients alive with CR, PR and SD according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) at 3 months	—

Secondary

Measure	Time frame
Percentage of patients with CR and PR, including duration hereof using RECIST v 1.1, Median PFS and OS, Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE) v5.0, The 30 item European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ C30) questionnaire	—

Countries

Denmark, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026